IDEAYA Biosciences Announces Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced it has presented data from an ongoing Phase 1/2 clinical trial entitled "A Phase 1/2 Study in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions" (ClinicalTrials.gov Identifier: NCT03947385)

Benzinga · 11/20/2019 11:07